Top Medical News
16 hours ago
Paravertebral block induced by levobupivacaine alone results in a longer time-to-block onset and reduced haemodynamic disruptions in breast cancer patients undergoing quadrantectomy compared with levobupivacaine combined with lidocaine, a new study has found.
Roshini Claire Anthony, 20 hours ago

Initiating therapy with fluticasone furoate plus vilanterol resulted in improved asthma control over usual care in individuals with symptomatic asthma, according to results of the Salford Lung Study presented at ERS 2017.

Jairia Dela Cruz, Yesterday
Use of sirukumab at 100 mg every 2 weeks and 50 mg every 4 weeks may yield significant reductions in rheumatoid arthritis (RA) symptoms, according to the SIRROUND-D study. The drug inhibits structural damage progression and improves physical function and quality of life in patients refractory to conventional disease-modifying antirheumatic drugs (DMARDs), while demonstrating an acceptable safety profile.
Audrey Abella, Yesterday
Insulin degludec/insulin aspart reduced the rates of overall and nocturnal severe hypoglycaemia compared with biphasic insulin aspart 30 in Muslim individuals with type 2 diabetes mellitus (T2DM) who fast during Ramadan, according to data presented at EASD 2017.
Pearl Toh, 2 days ago
Ertugliflozin 15 mg once daily is noninferior to the sulphonylurea glimepiride in HbA1c reduction over 52 weeks in patients with type 2 diabetes (T2D) who are inadequately controlled on metformin, according to the VERTIS SU* trial presented at the EASD 2017 in Lisbon, Portugal.
Tristan Manalac, 2 days ago
Obesity appears to decrease the risk of all-cause death in patients receiving statins after acute myocardial infarction, a recent study from Korea has shown.
2 days ago
Higher body fat content at baseline in patients with ankylosing spondylitis (AS) is likely to weaken response to treatment with tumour necrosis factor-α (TNF-α) blockers, measured by the Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), suggests a recent study.
Special Reports
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 31 Aug 2017
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
01 Aug 2017
Complementary medicines are popular among consumers in Malaysia so it is important for pharmacists to be well versed in complementary medicines.
Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 12 Jul 2017
Coronary artery disease (CAD) is the leading cause of death worldwide and is expected to remain so for the foreseeable future due to both the ageing population and the increasing prevalence of risk factors such as hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk factor in the development of heart failure (HF). At the 2nd Asia Pacific CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of international and regional experts discussed current strategies for managing stable CAD and HF and highlighted areas where patient outcomes may be improved.
12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
01 Jul 2017
At the recent launch of Nurofen® Express by Reckitt Benckiser Malaysia, Ms Joyce McSwan spoke on the importance of managing tension-type headache (TTH), highlighting the roles of drug and non-drug approaches in improving treatment outcomes.
22 Jun 2017
The University of Science, Malaysia (USM) team, led by Professor Dr Lee Yeong Yeh was recognized for its outstanding research submission that links poor hygiene practices in flood-affected areas to the increased risk in communicable intestinal infections in parts of Malaysia.
Conference Reports
Roshini Claire Anthony, 21 Sep 2017

Initiating therapy with fluticasone furoate plus vilanterol resulted in improved asthma control over usual care in individuals with symptomatic asthma, according to results of the Salford Lung Study presented at ERS 2017.

Audrey Abella, 21 Sep 2017
Insulin degludec/insulin aspart reduced the rates of overall and nocturnal severe hypoglycaemia compared with biphasic insulin aspart 30 in Muslim individuals with type 2 diabetes mellitus (T2DM) who fast during Ramadan, according to data presented at EASD 2017.
Pearl Toh, 20 Sep 2017
Ertugliflozin 15 mg once daily is noninferior to the sulphonylurea glimepiride in HbA1c reduction over 52 weeks in patients with type 2 diabetes (T2D) who are inadequately controlled on metformin, according to the VERTIS SU* trial presented at the EASD 2017 in Lisbon, Portugal.
Roshini Claire Anthony, 19 Sep 2017

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Audrey Abella, 19 Sep 2017
The oral dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin reduced the rates of progression to chronic insulin therapy (a continuous period of insulin use beyond 3 months), in patients with type 2 diabetes mellitus (T2DM) on metformin or sulfonylurea mono- or dual therapy compared with placebo, according to data presented at EASD 2017.
Roshini Claire Anthony, 18 Sep 2017

The addition of the sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) inhibitor sotagliflozin improved glycated haemoglobin levels, systolic blood pressure, and weight in patients with type 1 diabetes (T1D) on insulin therapy, according to findings of the InTandem3* trial presented at EASD 2017.

Pearl Toh, 15 Sep 2017
The GLP-1* receptor agonist dulaglutide confers comparable glycaemic control with greater albuminuria reduction and less eGFR** decline compared with insulin glargine in patients with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD), when both were used in combination with the human insulin analogue lispro, according to the AWARD-7 study presented at the EASD Annual Meeting 2017 in Lisbon, Portugal.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD